Bio-Path Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-9.89	-16.08	-13.87	-10.44	-10.88	Upgrade
Depreciation & Amortization	0.16	0.18	0.18	0.16	0.15	Upgrade
Stock-Based Compensation	0.57	0.73	0.85	0.82	0.58	Upgrade
Other Operating Activities	-2.08	0.27	-	-	-	Upgrade
Change in Accounts Payable	1.41	0.23	0.7	-0.2	-0.08	Upgrade
Change in Other Net Operating Assets	-0.73	3.13	-2.96	-0.26	-0.72	Upgrade
Operating Cash Flow	-10.58	-11.54	-15.1	-9.92	-10.96	Upgrade
Capital Expenditures	-	-	-0.02	-0.07	-	Upgrade
Investing Cash Flow	-	-	-0.02	-0.07	-	Upgrade
Issuance of Common Stock	10.7	2.2	1.73	20.01	4.29	Upgrade
Financing Cash Flow	10.7	2.2	1.73	20.01	4.29	Upgrade
Net Cash Flow	0.12	-9.33	-13.39	10.02	-6.67	Upgrade
Free Cash Flow	-10.58	-11.54	-15.12	-9.99	-10.96	Upgrade
Free Cash Flow Per Share	-4.40	-24.13	-41.55	-29.70	-56.98	Upgrade
Levered Free Cash Flow	-5.97	-5.52	-9.85	-5.98	-6.81	Upgrade
Unlevered Free Cash Flow	-5.97	-5.52	-9.85	-5.98	-6.81	Upgrade
Change in Net Working Capital	-0.8	-3.47	2.17	0.36	0.72	Upgrade

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.